Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.

Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.

Clin Cancer Res. 2005 Mar 15;11(6):2163-8.

2.

Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ.

Barnes NL, Boland GP, Davenport A, Knox WF, Bundred NJ.

Br J Surg. 2005 Apr;92(4):429-34.

PMID:
15736216
3.

COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.

Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ.

Br J Cancer. 2004 Jan 26;90(2):423-9.

4.

Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.

Prasad R, Boland GP, Cramer A, Anderson E, Knox WF, Bundred NJ.

Cancer. 2003 Dec 15;98(12):2539-46.

5.

Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.

Boland GP, McKeown A, Chan KC, Prasad R, Knox WF, Bundred NJ.

Br J Cancer. 2003 Jul 21;89(2):277-83.

6.

Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.

Boland GP, Chan KC, Knox WF, Roberts SA, Bundred NJ.

Br J Surg. 2003 Apr;90(4):426-32.

PMID:
12673743
7.

Molecular markers and therapeutic targets in ductal carcinoma in situ.

Boland GP, Knox WF, Bundred NJ.

Microsc Res Tech. 2002 Oct 1;59(1):3-11. Review.

PMID:
12242692

Supplemental Content

Loading ...
Support Center